Oncology
|
Each year 6.5 million people are diagnosed with cancer and over four million die worldwide as a result. Karolinska Development’s oncology portfolio includes several exciting new treatments that could lead to improvements in cancer care.
|
| Oncology | Concept Development | Lead Discovery | Lead Optimization | Preclinical Development | Phase I | Phase II | Phase III | Launch | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||
KDev Oncology AB (AKN-028) |
|
|||||||||||||||
|
|
||||||||||||||||
|
|
||||||||||||||||
KDev Oncology AB (GliGene) |
|
|||||||||||||||
Aprea ABAprea is developing pharmaceuticals that reactivate the p53 protein, which is damaged in many types of cancer. www.aprea.com |
Axelar ABAxelar is developing a cancer drug that inhibits the Insulin-like Growth Factor 1 receptor (IGF-1). www.axelar.se |
KDev Oncology ABAkinion Pharmaceuticals is developing FLT-3 kinase inhibitors for cancer treatment. www.akinion.com |
||
Oncopeptides ABOncopeptides has developed a series of patented oligopeptides for cancer treatment. www.oncopeptides.se |
KDev Oncology ABGliGene is developing antagonists to the Hedgehog pathway for the treatment of solid tumors. |
|
1) Source: WHO, International Agency for Research on Cancer, Globocan, 2008, http://globocan.iarc.fr